- Conditions
- HIV-1-infection
- Interventions
- Blood collection, Abacavir/lamivudine, Tenofovir alafenamide/emtricitabine, Switch
- Other · Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 518
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Hepatitis B
- Interventions
- TDF, Peg-IFN
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 751 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 17 more
- Conditions
- Hepatitis B
- Interventions
- Tenofovir, Peginterferon-alfa 2a and tenofovir
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 20
- States / cities
- Los Angeles, California • San Francisco, California • Honolulu, Hawaii + 11 more
- Conditions
- Opioid Use Disorder, HIV, Hepatitis C Virus, Gonorrhea, Chlamydia, Syphilis, Sexually Transmitted Infection, Integrated Care, Medications for Opioid Use Disorder
- Interventions
- Integrated care
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2028 – 2029
- U.S. locations
- 1
- States / cities
- Northport, New York
- Conditions
- HIV-Associated Focal Segmental Glomerulosclerosis, HIV-Associated Collapsing Glomerulopathy, Proteinuria, Albuminuria, Renal Tubular Toxicity
- Interventions
- Not listed
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 8 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- HIV-1 Infection
- Interventions
- ABC/DTG/3TC, B/F/TAF, ABC/DTG/3TC Placebo, B/F/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 631 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more
- Conditions
- Chronic Hepatitis B
- Interventions
- ABI-H0731, Placebo, NrtI
- Drug
- Lead sponsor
- Assembly Biosciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Pasadena, California • San Diego, California + 6 more
- Conditions
- HIV-1-infection
- Interventions
- Bavtavirine, B/F/TAF, Standard of Care (Substudy 01), GS-1720, Standard of Care (Substudy 02), GS-6212, Standard of Care (Substudy 03)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 38
- States / cities
- Long Beach, California • Los Angeles, California • San Francisco, California + 14 more
- Conditions
- Safety Issues
- Interventions
- TAF/EVG rectal insert, Matching placebo rectal insert
- Drug
- Lead sponsor
- Eastern Virginia Medical School
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- HIV-1-infection
- Interventions
- GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 40 more
- Conditions
- HIV-1 Infections
- Interventions
- TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily, TDF/FTC + Efavirenz (Atripla) Once-Daily
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years to 60 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 5
- States / cities
- Chicago, Illinois
- Conditions
- HIV Infections
- Interventions
- Single dose of Genvoya® and a single 800 mg dose of Darunavir®
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 49 Years · Male only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- HIV Infection
- Interventions
- abacavir/lamivudine/zidovudine, tenofovir
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 27
- States / cities
- Los Angeles, California • San Rafael, California • Fort Lauderdale, Florida + 22 more
- Conditions
- HIV Infection
- Interventions
- efavirenz, tenofovir, abacavir/lamivudine
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 58
- States / cities
- Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 42 more
- Conditions
- HIV Infections
- Interventions
- Truvada (tenofovir DF + emtricitabine), Emtriva (emtricitabine), Viread (tenofovir DF)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 4
- States / cities
- Fort Lauderdale, Florida • Vero Beach, Florida • Baltimore, Maryland + 1 more
- Conditions
- Hepatitis B
- Interventions
- TDF, FTC/TDF, TDF Placebo, FTC/TDF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 3
- States / cities
- Bradenton, Florida • Flushing, New York • Philadelphia, Pennsylvania
- Conditions
- Chronic Hepatitis B
- Interventions
- TAF, TDF, TAF Placebo, TDF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 490 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Palo Alto, California • Pasadena, California + 11 more
- Conditions
- HIV Infections
- Interventions
- Tenofovir disoproxil fumarate
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 0 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 19
- States / cities
- Berkeley, California • Los Angeles, California • San Francisco, California + 16 more
- Conditions
- HIV/AIDS, Adherence, Medication
- Interventions
- Digital Pill
- Device
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Hepatitis B, Chronic
- Interventions
- JNJ-73763989, Placebo for JNJ-73763989, JNJ-56136379, Placebo for JNJ-56136379, Nucleos(t)ide Analog (NA)
- Drug
- Lead sponsor
- Janssen Sciences Ireland UC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 471 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 8
- States / cities
- Bakersfield, California • Los Angeles, California • San Clemente, California + 5 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Fatigue
- Interventions
- TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY], Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Multiple Sclerosis
- Interventions
- Truvada (tenofovir/emtricitabine)
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- HIV Infection
- Interventions
- Nucleoside analogue switch
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- HIV/AIDS, Contraception
- Interventions
- tenofovir/emtricitabine, DMPA
- Combination Product · Drug
- Lead sponsor
- Sharon Achilles
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania